LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/DePuy Synthes Adds Cementless Option for ATTUNE Knee
Large Joints and Extremities

DePuy Synthes Adds Cementless Option for ATTUNE Knee

September 13, 2019 2 min read Premium comments

Advertisement

DePuy Synthes Adds Cementless Option for ATTUNE Knee
Rajit Kamal, Vice President and Global Franchise Knee Leader, DePuy Synthes, holds the rotating platform tibial base of the ATTUNE Cementless Knee. / Courtesy of DePuy Synthes
Secondary#attunekneesystem#biologicfixation#porocoat

Johnson & Johnson Medical Devices Companies has announced that DePuy Synthes is launching the ATTUNE Cementless Knee in a rotating platform option in certain global markets.

“The ATTUNE Cementless Knee has the same great kinematic features of the cemented ATTUNE Knee, but I feel the cementless technology is a better alternative for my younger and more active patients who have healthy, strong bones,” said Ryan M. Nunley, M.D., Associate Professor and Fellowship Director at Washington University Orthopedics, Barnes Jewish Hospital. “These patients have the potential to remain active for many decades, and I think the evidence is growing that cementless knees have good long-term durability. I’ve implanted more than 400 ATTUNE Cementless Knees in my practice with excellent early results.”

As stated in the press release, “As with the cemented primary and revision systems, the ATTUNE Cementless Knee features several patented technologies designed to improve knee function. These include the ATTUNE GRADIUS Curve to provide stability through the range of motion and GLIDERIGHT Articulation to more accurately replicate the normal relationship between the patella (knee cap) and femur.”

“In developing the ATTUNE Cementless Knee, DePuy Synthes drew on the successful clinical history and legacy of its cementless and rotating platform technologies, including the LCS Cementless Knee which features POROCOAT Porous Coating which allows for biologic fixation.”

“The ATTUNE Cementless Knee is initially being launched in the United States, select countries in Europe, Japan, Australia and New Zealand, with additional launches to follow. It is available in a Cruciate Retaining and Posterior Stabilized Rotating Platform construct as well as a hybrid construct (cementless Femoral Component with a cemented Fixed Bearing or Rotating Platform Tibial base).”

Rajit Kamal, vice president and global franchise leader, Knees, DePuy Synthes, described some of the features of the cementless Attune knee to OTW, “There are several patented technologies that are part of the ATTUNE Knee and are meant to return patients to freedom and movement.”

“Among these are ATTUNE GRADIUS Curve, which is designed to address the unnatural sliding of the femur on the tibia to provide smooth motion and stability for everyday activities like going up and down the stairs and getting up from a chair. Another patented technology is GLIDERIGHT Articulation which is designed to enable the ATTUNE Knee design to more accurately replace the normal patella-femoral kinematics of the native knee so that the patient’s movements may be as smooth as possible.”

“Cementless knee surgeons who use rotating platform now have a device that combines the technologies of the ATTUNE Knee and learnings from our clinically successful predicate devices, including the LCS COMPLETE Knee System.”

Advertisement

“The patented ATTUNE Knee technologies as well as our leadership in rotating platforms and long history with POROCOAT, which allows for biologic fixation, differentiate ATTUNE Cementless from other cementless technologies on the market.”

Dr. Ryan Nunley is a consultant to DePuy Synthes Joint Reconstruction. Rajit Kamal is employed by Medical Device Business Services, Inc.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy